MECHANISM OF DEATH IN HEART-FAILURE - THE VASODILATOR-HEART FAILURE TRIALS

被引:0
|
作者
GOLDMAN, S
JOHNSON, G
COHN, JN
CINTRON, G
SMITH, R
FRANCIS, G
机构
[1] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES COORDINATING, West Haven, CT USA
[2] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES COORDINATING, MINNEAPOLIS, MN USA
[3] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES, TAMPA, FL USA
[4] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES COORDINATING, NASHVILLE, TN USA
关键词
CLINICAL TRIALS; HEART FAILURE; MORBIDITY; MORTALITY; SUDDEN DEATH;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The Vasodilator-Heart Failure Trial (V-HeFT) data base provides information on the mechanism of death of male veterans entered into two trials that evaluated the effect of vasodilator therapy on survival in heart failure. Methods and Results. Men aged 18-75 years with heart failure were recruited at 13 Department of Veterans Affairs Medical Centers. In V-HeFT I, 283 of 642 patients (44%) died during follow-up (average, 2.3 years), and in V-HeFT II, 285 of 804 randomized patients (35.5%) died during follow-up (average, 2.5 years). Mechanism of death was established centrally using a standardized classification. In V-HeFT I, 124 of the 283 deaths (43.8%) were sudden with no worsening of symptoms; in V-HeFT II, 104 of the 285 deaths (36.5%) were sudden. An average of 31.5% of the deaths (31.4% and 31.6%, respectively) in the two trials was due to pump failure. The proportion of sudden deaths that occurred without worsening of symptoms was similar in patients with and without ischemic heart failure. Sudden deaths tended to occur earlier and pump failure deaths later in both V-HeFT studies. There was a trend for a lower percentage of cardiac deaths from pump failure and a higher percentage from sudden death in subgroups with higher peak exercise oxygen consumption (VO2), higher ejection fraction, and lower plasma norepinephrine levels. The proportion of deaths that occurred suddenly was similar in placebo, prazosin, and hydralazine plus isosorbide dinitrate treatment groups but was significantly lower in the enalapril treatment group. In V-HeFT I, measures of cardiac function and VO2 predicted pump failure death and sudden death. In V-HeFT II, VO2 and cardiothoracic ratio were independent predictors of all-cause deaths and pump failure deaths; only ejection fraction was an independent predictor of both pump failure and sudden death. Conclusion. Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms. Strategies to identify individuals for selective preventive therapy are not yet practical.
引用
收藏
页码:24 / 31
页数:8
相关论文
共 50 条
  • [1] HEART-FAILURE IN 1991
    FRANCIS, GS
    CARDIOLOGY, 1991, 78 (02) : 81 - 94
  • [2] The Current Focus of Heart Failure Clinical Trials
    Pothineni, Naga Venkata
    Kattoor, Ajoe John
    Kovelamudi, Swathi
    Kenchaiah, Satish
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (05) : 321 - 329
  • [3] How robust are clinical trials in heart failure?
    Docherty, Kieran F.
    Campbell, Ross T.
    Jhund, Pardeep S.
    Petrie, Mark C.
    McMurray, John J. V.
    EUROPEAN HEART JOURNAL, 2017, 38 (05) : 338 - +
  • [4] Rethinking heart failure clinical trials: the heart failure collaboratory
    Alkalbani, Mutaz
    Psotka, Mitchell A.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [5] HEART-FAILURE IN WOMEN
    KIMMELSTIEL, CD
    KONSTAM, MA
    CARDIOLOGY, 1995, 86 (04) : 304 - 309
  • [6] Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
    Zannad, Faiez
    Garcia, Angeles Alonso
    Anker, Stefan D.
    Armstrong, Paul W.
    Calvo, Gonzalo
    Cleland, John G. F.
    Cohn, Jay N.
    Dickstein, Kenneth
    Domanski, Michael J.
    Ekman, Inger
    Filippatos, Gerasimos S.
    Gheorghiade, Mihai
    Hernandez, Adrian F.
    Jaarsma, Tiny
    Koglin, Joerg
    Konstam, Marvin
    Kupfer, Stuart
    Maggioni, Aldo P.
    Mebazaa, Alexandre
    Metra, Marco
    Nowack, Christina
    Pieske, Burkert
    Pina, Ileana L.
    Pocock, Stuart J.
    Ponikowski, Piotr
    Rosano, Giuseppe
    Ruilope, Luis M.
    Ruschitzka, Frank
    Severin, Thomas
    Solomon, Scott
    Stein, Kenneth
    Stockbridge, Norman L.
    Stough, Wendy Gattis
    Swedberg, Karl
    Tavazzi, Luigi
    Voors, Adriaan A.
    Wasserman, ScottM.
    Woehrle, Holger
    Zalewski, Andrew
    McMurray, John J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (10) : 1082 - 1094
  • [7] HEART-FAILURE AND ARRHYTHMIAS
    ROSTOCK, KJ
    ZEITSCHRIFT FUR KARDIOLOGIE, 1991, 80 : 27 - 30
  • [8] CARVEDILOL IN HEART-FAILURE
    KELLY, DT
    CARDIOLOGY, 1993, 82 : 45 - 49
  • [9] SUDDEN-DEATH IN HEART-FAILURE - ANALYSIS AND PREVENTION
    AUMONT, MC
    COHENSOLAL, A
    HIMBERT, D
    STEG, PG
    PAILLOLE, C
    PRESSE MEDICALE, 1992, 21 (01): : 33 - 38
  • [10] Representation of Black patients in heart failure clinical trials
    Azam, Tariq U.
    Colvin, Monica M.
    CURRENT OPINION IN CARDIOLOGY, 2021, 36 (03) : 329 - 334